SDF1 has previously been shown to be a potent activator of PI3K and MAPK signaling28, and indeed targets of these pathways are significantly more phosphorylated upon SDF1 treatment of MDS CD34 + cells. The gene discussed is CXCL12; the disease is myelodysplastic syndrome.